Read at: Fierce →
ON LINKEDIN
Join us tomorrow, Wednesday, November 18, at 10:00 AM ET / 7:00 AM PT / 3:00 PM GMT for a fireside chat at the Jefferies Global Healthcare Conference in London, featuring our Founder & CEO Sean McClain and Zach Jonasson, PhD, CFO & CBO. The conversation will focus on the clinical and strategic outlook for ABS-201 ahead of our upcoming data readout in December. Sean and Zach will discuss progress in our Phase 1/2a HEADLINE™ trial, the anticipated interim proof-of-concept data in androgenetic alopecia (pattern hair loss), and our potential across two large, underserved markets: pattern hair loss and endometriosis. View the Webcast: https://lnkd.in/g9_dx6yS
We’re excited to welcome Gerry Muhle as Absci’s Chief Commercial Officer! Gerry brings a track record of global leadership launching and scaling brands across prescription medicines, aesthetics, and consumer products. He joins us from Galderma, where he led global commercial and product strategy across the company’s entire portfolio, and previously held commercial leadership positions at AbbVie, Allergan, and GSK. At Absci, he will lead our commercial strategy, advancing our pipeline and ABS-201 program for pattern hair loss and endometriosis. Join us in giving Gerry a warm welcome!
Absci’s ABS-201 program was featured in a recent Esquire magazine article on the unmet need in androgenetic alopecia treatments. As the piece notes, approved treatments for pattern hair loss have seen limited innovation in the last 30 years. ABS-201, an AI-designed antibody from Absci currently in Phase 1/2a trials, takes a different approach: a novel, investigational mechanism of action targeting the prolactin receptor. Read the article "The Bald Truth About the Generative Era of Hair Loss" to learn more about the treatment landscape and patient impact of pattern hair loss. Read now: https://lnkd.in/g4XqCsvm